… cell lines to the allosteric SHP2 inhibitor SHP099. Sensitivity to SHP099 in … high-risk NB
tumors regardless of MYCN status. SHP2 inhibition consistently blocks tumor growth in high-risk …

… These findings suggest that conventional therapy–resistant, relapsed neuroblastoma
may be effectively treated via combined inhibition of SHP2 and MEK or ERK of the RAS–MAPK …

… RAS mutational status correlates with SHP2 inhibitor sensitivity in NB cells ......... 31 2.3.2 …
to SHP2 inhibition ................... 36 2.3.3 NRASQ61K confers resistance to SHP2 inhibitors .............…

… RAS mutational status correlates with SHP2 inhibitor sensitivity in NB cells ......... 31 2.3.2 …
to SHP2 inhibition ................... 36 2.3.3 NRASQ61K confers resistance to SHP2 inhibitors .............…

… -activated or mutant SHP2 in human neuroblastomagenesis. … inhibition of MYCN and the
SHP2-RAS-ERK pathway could provide effective targeted therapy for high-risk neuroblastoma …

… that SHP2 inhibitors SHP099 and TNO155 show higher selectivity in ALK-mutant neuroblastoma
… Importantly, TNO155 showed substantially higher single-agent antitumor activity than …

… Using this combined approach, we identified a role for SHP-2 and … their involvement in
neuroblastoma cell differentiation. … an inhibitory role for the E3 ligase Cbl-b in neuroblastoma …

… (F) SHP-099 binds to SHP2 to inhibit RAS activation, green represents SHP-099 (PDB:
5EHR ). (For interpretation of the references to colour in this figure legend, the reader is referred …

… associated with an increased risk for malignancies, including leukemia and neuroblastoma
… in the preclinical and clinical development of SHP2 inhibitors, as well as their potential role in …

… progress in discovery of SHP2 inhibitors in cancer therapy. … Even so, two types of SHP2
inhibitors including targeting … recent advance in development of SHP2 inhibitors, trying to give an …